Enlivex is making a bold move into digital assets, raising $21 million through a debt deal to expand its holdings in the prediction market token RAIN.
The company used part of that funding to buy another 3 billion RAIN tokens for $10 million—at a steep 62% discount. On top of that, it secured the right to purchase up to 272.1 billion more tokens at the same price, with the option open until December 2027.
This funding came from The Lind Partners, giving Enlivex more flexibility to push forward with what it calls its “prediction markets treasury strategy.” According to executive chair Shai Novik, the goal is to keep building both its core business and its growing crypto holdings.
At the same time, Enlivex announced a $20 million share buyback plan. The idea is to support its stock price while it continues investing in digital assets.
Even though Enlivex is known for developing treatments for conditions like knee osteoarthritis, it’s now part of a growing trend—companies outside the crypto space adding tokens to their balance sheets as part of their financial strategy.
The value of its RAIN holdings depends heavily on activity on the Rain platform, which runs on Arbitrum. The platform charges a 2.5% fee and uses it to buy back and burn tokens, reducing supply and potentially boosting value over time.
Prediction markets themselves are growing fast. Trading volume has surged over the past year, showing increasing interest in platforms where users can bet on real-world outcomes.
After the announcement, RAIN saw a small bump—rising briefly before leveling off. Enlivex shares didn’t move much during regular trading but ticked higher in after-hours activity.
Meanwhile, platforms like Kalshi and Polymarket still dominate the space, accounting for the majority of trading volume.
Overall, Enlivex is taking a high-risk, high-reward approach—blending biotech with crypto in a way that could pay off big, but also comes with uncertainty.
